bone (extracanalicular). Extracanalicular VSs may extend into the cerebellopontine angle, causing symptoms due to mass effect. Patients most typically present with hearing loss and tinnitus, occurring in 95% and > 60% of cases, respectively. 40 Disequilibrium, vertigo, and dizziness may also occur, especially with large VSs. Other cranial nerve deficits are not uncommon, with 12%-19% of patients having signs of trigeminal dysfunction and 17% having facial neuropathy with larger tumors. Evaluation typically involves Gd-enhanced MRI studies, with audiometric and vestibular testing performed prior to or after imaging. 11 Once suspected, there are a variety of treatment options for tumor management. This includes observation with the use of serial MRIs, microsurgical resection, stereotactic radiosurgery, and fractionated radiotherapy. The choice of treatment is dependent on patient age, health status, clinical symptoms, tumor size, and patient preference. However, physician bias has been shown to significantly affect treatment choice for VS, similar to findings seen in other tumors. 33, 34 This may be due to the paucity of evidence-based guidelines and randomized controlled trials.
In this study we describe the current epidemiology of VS and treatment trends in the US in the modern era. We also illustrate patient and tumor characteristics and elucidate their effect on tumor management.
Methods

Patient Population
We used data from the US National Cancer Institute's SEER Program, using the SEER 18 Registries data from 1973 to 2009. This comprehensive database includes 28% of the population and is the gold standard for cancer registries. 27 It is also the only comprehensive source of cancer incidence and patient survival data in the US, collecting these data from 18 population-based cancer registries. However, nonmalignant CNS tumors were only added to case definitions in the SEER database as of January 1, 2004 . This study used data from the most recent data set, covering the years 2004 through 2009.
Patients with "neurilemmoma" and "neuroma" were selected using the ICD for Oncology (ICD-O) codes 9560 and 9570, respectively. We then retained those with tumor primary site listed as the "acoustic nerve" as coded by the ICD-O topography code C72.4, forming our primary cohort. We excluded patients who were not active followup cases to eliminate patient data recorded at autopsy or from death certificates. A total of 6225 patients with VS met the inclusion criteria and were analyzed.
Statistical Analysis
Various patient, tumor, and treatment characteristics were evaluated including age, sex, race, tumor size and laterality, method of diagnosis (histological or via direct visualization, imaging, or clinical signs), and treatment including the use of radiation therapy or resection. Tumor size recorded as > 10 cm was considered inaccurate and therefore classified as "unknown." These 27 cases were excluded from the univariate and multivariate analyses. Age-adjusted incidence rates were calculated using SEER*Stat software and were adjusted using the 2000 US standard population. The chi-square and Student ttests were used to evaluate differences between patient and tumor characteristics. Multivariate logistic regression was performed to determine the effects of various patient and tumor characteristics on the choice of tumor treatment. Univariate and multivariate regression was also used to determine the effect of patient characteristics on tumor size at presentation. Case-level data were concatenated and analyzed using SAS version 9.3 software (SAS Institute).
Results
Epidemiology of VS
A total of 6225 patients diagnosed with VS between 2004 and 2009 (Table 1) were identified. The overall incidence rate was 1.2 per 100,000 population per year. Incidence rates were comparable for males and females, with each having an incidence of 1.2 per 100,000 per year. Caucasian patients had the highest VS incidence (1.3/100,000/yr), with those of other races (1.2/100,000/ yr) having a similar incidence. However, African American patients (0.5/100,000/yr) had an incidence less than half that of other races.
Patient, Tumor, and Treatment Characteristics in the US
The median age of patients with VS was 55 years, ranging from 4 to 103 years ( Table 1 ). The incidence of VS increased with age, peaking in the 6th decade of life, with these patients representing 28.24% of the cases. The majority of patients were Caucasian (83.16%), with African American patients only accounting for 4.27% of cases. There were significantly more females, comprising 51.98% of VS cases, compared with 48.02% for males (p = 0.0017). The median tumor size was 1.6 cm, with tumors most frequently measuring between 1 and 1.9 cm (27.71% of cases). Large VSs (≥ 3 cm) were present in 19.4% of cases with known tumor sizes. There was no difference in the occurrence of VS due to tumor location (left or right), with 16 patients (0.26%) having bilateral tumors; by definition these patients had neurofibromatosis Type 2. Of all patients with VS, 3053 (49.04%) received surgery only, and 1466 (23.55%) received radiotherapy alone. Both surgery and radiation were used in only 123 patients (1.98%), while 1504 patients (24.16%) did not undergo any treatment. Over the examined time period (2004) (2005) (2006) (2007) (2008) (2009) , the percentage of cases treated surgically declined from 56% to 48.8%, with radiotherapy use increasing from 21.6% to 25.2% of cases (Fig. 1) . The rates of observation also increased, with 20.7% of patients diagnosed in 2004 undergoing conservative management compared with 24.4% of patients diagnosed in 2009. Patients were diagnosed via histological examination or direct visualization in 56.14% of cases, whereas diagnosis with imaging only occurred in 42.46%.
Patient and Tumor Characteristics by Treatment Type
Treatment choice was significantly affected by age (Table 2) . Patients who only received surgery were younger than those who only received radiation (51 vs 58 years, p < 0.0001). However, those who received both surgery and radiation were similar in age to patients who only received surgery (50 vs 51 years, p = 0.096). Patients who did not receive any treatment were significantly older, with a median age of 62 years compared with 53 years for those who did receive treatment (p < 0.0001). Observation was the most common management strategy for those 10 years and younger (70.6%), with surgery being the most commonly used treatment modality for those ages 11-70 years (surgery, 56.6%; observation, 19.7%). For those 81 years and older, observation (65.9%) was most commonly used, followed by radiotherapy.
Examination of the effect of race on tumor management revealed disparities. Approximately half of all Caucasian patients received surgery (50.2%), with only 39.1% of African American patients receiving surgery (p = 0.0004). Patients of other races received surgery at a comparable rate to Caucasians (p = 0.63). No significant differences were seen between the races with respect to the use of radiotherapy. Although most patients who received both surgery and radiation were Caucasian, patients of other races received this management strategy significantly more frequently (1.8% vs 3%, p = 0.048). The rate of surgery and radiation use did not differ significantly for African American patients compared with Caucasians and those of other races. However, African American patients underwent tumor observation (30.8%) at significantly higher rates than Caucasians (23.7%) and patients of other races (22.1%) (p = 0.0074 and 0.0052, respectively). No significant difference in tumor observation was seen between Caucasians and patients of other races. Also no sex disparities were seen in the use of treatment.
Those receiving surgery had significantly larger tumors compared with those who only received radiation (2 vs 1.5 cm, p < 0.0001). Patients receiving both surgery and radiation had a median tumor size of 3.5 cm, compared with 2 cm for those only receiving surgery (p < 0.0001). Also those receiving treatment had significantly larger tumors than those who did not receive surgery or radiation (1.9 vs 1.1 cm, p < 0.0001). Observation was the most common management strategy for those with tumors < 1 cm, occurring in 46.7% of cases. For those with tumors ≥ 1 cm, surgery was the most common treatment modality, with the rates of radiation use and conservative management decreasing with increasing tumor size.
Effect of Patient Factors on Tumor Size
Univariate linear regression revealed older age (p < 0.0001) and Caucasian race (p = 0.0067) to correlate significantly with decreased tumor size at presentation. In contrast, race other than Caucasian or African American was associated with increased tumor size (p < 0.0001). The median tumor size for Caucasians was 1.6 cm, compared with 1.8 and 1.9 cm for African Americans and patients of other races, respectively. Female sex (p = 0.94) and African American race (p = 0.32) were not seen to be significantly associated with tumor size. Multivariate linear regression only revealed older age and "other" race to correlate significantly with tumor size. As seen in the univariate analysis, age was associated with decreasing tumor size (p < 0.0001), with "other" race correlating with increased tumor size (p < 0.0001).
Effect of Patient Characteristics and Tumor Size on the Choice of Treatment
Multivariate logistic regression revealed age, race, and tumor size to significantly affect the use of surgery (Table 3) . Increasing age correlated with decreased use of surgery (OR 0.95, 95% CI 0.95-0.96; p < 0.0001). Similarly, African American patients were half as likely to receive surgery compared with Caucasian patients (OR 0.50, 95% CI 0.35-0.70; p < 0.0001). However, increasing tumor size was significantly associated with the increased use of surgery (OR 1.04, 95% CI 1.04-1.05; p < 0.0001). Female sex (OR 1.10, 95% CI 0.97-1.25; p = 0.13) and "other" race (OR 0.86, 95% CI 0.70-1.07; p = 0.18) did not significantly affect the likelihood of surgery.
The use of radiotherapy was significantly affected by age and tumor size. Older age was associated with an increased likelihood of receiving radiation (OR 1.02, 95% CI 1.02-1.03; p < 0.0001), whereas increasing tumor size was significantly associated with decreased radiation use (OR 0.98, 95% CI 0.98-0.99; p < 0.0001). Female sex and race were not found to correlate with the use of radiotherapy. Similar to the results found for receiving surgery only, increasing age was significantly associated with a decreased likelihood of receiving both surgery and radiation (OR 0.97, 95% CI 0.96-0.99; p = 0.0002), whereas tumor size correlated with an increased likelihood of receiving both therapies (OR 1.06, 95% CI 1.05-1.07; p < 0.0001).
Age, race, and tumor size significantly correlated with the use of observation for tumor management. Increasing age was associated with an increased likelihood of conservative management (OR 1.04, 95% CI 1.04-1.05; p < 0.0001). Similarly, African American race correlated with an increased use of observation, with these patients being nearly twice as likely as Caucasians to receive conservative management (OR 1.98, 95% CI 1.37-2.85; p = 0.0003). However, increasing tumor size was significantly associated with the decreased use of observation (OR 0.93, 95% CI 0.92-0.94; p < 0.0001).
Discussion
The decisions regarding the management of VSs are complex and pose significant challenges to neurosurgeons. The course of treatment is affected by patient factors including age and functional status, tumor characteristics such as size and location, and patient preference. Additionally, institutional and physician biases may affect the treatment course. As a result, the nationwide treatment strategies for VSs and the factors that affect treatment choice are unclear. This study of 6225 patients is the largest epidemiological examination of VSs and associated treatment trends in the US in the modern era. Additionally, it elucidates patient and tumor characteristics that affect the choice of treatment.
The incidence of VS was 1.2 per 100,000, similar to data from the Central Brain Tumor Registry of the United States (CBTRUS) and the Los Angeles County Cancer Surveillance Program (LACCSP). 37 Propp et al. showed the incidence of VS to be 0.6 per 100,000 person-years in the CBTRUS data, while the LACCSP data showed an incidence of 0.8 per 100,000 person-years. However, the incidence of VS varies with geographic region and time period, with worldwide rates ranging from 1 to 20 cases per million population per year. 18, 23, 51, 52 Studies from Denmark have shown the incidence of VS to range from 0.78 to 1.24 per 100,000 population per year during the years 1976-1995, with a more recent study demonstrating the incidence to range from 0.3 to 2.3 per 100,000 per year between 1976 and 2008. 48, 51 Studies have also shown differences in VS incidence between Denmark, Finland, Norway, and Sweden, with rates ranging from 0.61 to 1.16 per 100,000 population per year. 23 The incidence of VS has been shown to be increasing, likely due to the advancement in noninvasive imaging techniques. 37, 48, 51 As a result of earlier detection, tumor size at diagnosis has decreased from 3 cm during 1979-1981 to 1 cm during 2003-2005, consistent with the median size (1.6 cm) seen in this study. 48 Although factors including loud noise and radiation exposure have been suggested to increase the risk of developing VS, the role of other factors in increasing the incidence of VS is unknown. 36, 39 The management of VSs is challenging as neurosur- geons must balance the risk of hearing loss, increased vestibular symptoms, and facial weakness with treatment side effects and complications. Microsurgical resection is frequently performed to manage these tumors, typically via the retrosigmoid, translabyrinthine, or middle cranial fossa approaches. These procedures are complex and have the potential to lead to negative outcomes. A systematic review of the literature revealed a 0.2% mortality rate, with 22% of patients experiencing 1 significant postoperative complication. 49 Additionally, the rates of facial paralysis and weakness with surgery were 8% and 14%, respectively. In another study, the Nationwide Inpatient Sample was used to evaluate 4886 patients who underwent VS resection, demonstrating a mortality rate of 0.5% and a facial nerve disorder rate of 25%. 29 Older age and surgeon case load were significant predictors of death, with insurance status also predicting adverse discharge disposition. Now that we have a good understanding of the natural history of VS (for example, typical growth of < 2 mm/year) and long-term results showing reduced risks with stereotactic radiosurgery and fractionated radiotherapy, there is more focus on improving functional outcomes and reducing surgical morbidity by performing less aggressive resections. For example, tumor that is markedly adherent to surrounding structures such as the facial nerve may be spared, leaving a silhouette of tumor along the nerve (Fig.  2) . These so-called function-preserving approaches have been shown to significantly improve facial nerve outcomes following VS surgery. 28 Due to the frequent surgical risks of hearing loss and facial weakness, there is growing interest regarding the use of radiotherapy for the treatment of these tumors. Some literature suggests that microsurgery (in highvolume centers) and radiosurgery can have comparable rates of permanent facial paralysis (8% vs 7.7%), although microsurgery has a greater incidence of temporary facial weakness compared with radiosurgery (14% vs 4.8%). 56 The overall quality of life at 5-year follow-up was also significantly higher in those who underwent radiosurgery. 56 The few prospective studies investigating this question have also supported radiosurgery. A prospective study of 82 patients with VSs < 3 cm showed that patients who underwent radiosurgery were more likely to maintain normal facial function (96%) and serviceable hearing (63%) at last follow-up than those who received microsurgical treatment (75% and 5%, respectively). 35 Also, patients who underwent surgical treatment had significantly lower scores in physical functioning, pain, and energy/fatigue. Another prospective nonrandomized study evaluating 91 patients also concluded that radiosurgery resulted in better facial nerve and hearing function compared with surgical treatment for patients with small and medium-sized VSs. 31 In this study, 68% of patients who underwent radiotherapy had serviceable hearing 2 years after treatment, compared with 0% of those who underwent surgery. Also, reduced facial nerve function at 2 years was seen in 46.4% of patients who underwent surgery, compared with 1.7% of those who received radiation. Additionally, the quality of life was reported to be better in those receiving radiosurgery. Although these studies involved small patient cohorts and thus have limitations, they provide the highest-quality data for comparing the efficacy of microsurgery to radiosurgery.
Although radiosurgery may be superior to surgical treatment for the management of small and medium-sized VSs, it is not without risks and side effects. Treatment may result in the irradiation of nearby cranial nerves and brainstem structures. Whereas meta-analyses have reported rates of facial and trigeminal neuropathy up to 19% and 16%, more recent studies have shown mean rates of 1.5% and 1.2%, respectively. 2, 17, 22, 32, 38, 44, 57 This is most likely due to advances in radiotherapy, which have allowed for the use of lower doses and a more accurate dose conformality. 13 Hydrocephalus may occur in up to 4.4% of patients. 2, 3, 55 Also, tumor progression infrequently occurs despite treatment, with actuarial 10-year progression-free survival occurring in > 90% of patients. 7, 17, 25 Finally, a small risk (< 1%) of malignant transformation or radiation-induced neoplasms is present following radiosurgery. 41, 58, 59 Despite data suggesting the use of radiotherapy for the treatment of VSs < 3 cm, our data show that this is not the most common modality of treatment (Fig. 1) . Whereas the most common management strategy was observation for tumors < 1 cm, surgery was the most common treatment modality for all tumors 1-3 and > 3 cm. Although radiotherapy was most commonly used for patients with tumors sized 1-1.9 cm, this only accounted for 33.9% of cases. As a result, multivariate analysis revealed that larger tumor size increased the likelihood of surgical treatment (OR 1.04, 95% CI 1.04-1.05; p < 0.0001) while decreasing the use of radiotherapy (OR 0.98, 95% CI 0.98-0.99; p < 0.0001). As expected, increasing age was associated with decreased surgical management (OR 0.95, 95% CI 0.95-0.96; p < 0.0001) and increased likelihood of treatment with radiotherapy (OR 1.02, 95% CI 1.02-1.03; p < 0.0001) due to the increase in surgical complications in older patients. 29 In this study, only 23.3% and 30.4% of elderly patients (≥ 65 years) received surgery or radiotherapy alone, compared with 57.4% and 21.3%, respectively, of patients < 65 years.
Due to the benign nature (that is, slow growth rate and lack of parenchymal invasion) of VSs, elderly patients and those with small tumors frequently receive conservative management, a method in which serial MRI stud- ies are used to monitor tumor size. Our data confirm that those not receiving treatment were significantly older and had smaller tumors than those who did receive treatment. Also, the median size (1.1 cm) of VSs in the patients who underwent conservative treatment in this study is consistent with one of the largest meta-analyses of VS treatment performed, which demonstrated a mean tumor size of 1.18 cm in conservatively treated patients. 45 Elderly patients typically only undergo resection for large VSs that may exert mass effect on surrounding structures. Our data show that elderly patients receive surgical treatment for significantly larger tumor sizes than younger patients (median size 2.5 vs 2 cm, p = 0.0007). Studies have also characterized the natural history of VS, with meta-analyses reporting a mean overall growth rate of 1.8-1.9 mm/ year. 42, 45 However, the growth rate is heterogeneous, with many tumors not growing over a period of years. Subgroup analysis has revealed that tumors exhibiting signs of radiographic progression have a growth rate of up to 4 mm/year. 42 Also, volumetric analyses have been performed to quantify tumor growth rather than relying on a single diameter. A recent study comparing tumor growth models found that volume doubling time was a more realistic growth model compared with single-diameter and volume-based models. 53 This study found that a volume doubling time of 5.2 years best distinguished growing from nongrowing tumors. Patients with good serviceable cranial nerve function and tumors that do not grow for 5 years are likely never to require treatment. Nonetheless, strict observation is critical, with 43%-85% of tumors growing over a period of 3-4 years. 6, 45, 50 When considering the use of conservative management, patient selection is important. Because initial tumor size and growth are often the primary determinants for the treatment of patients who undergo conservative management, predictors of VS growth should be evaluated when making management decisions. In one of the largest studies evaluating tumor growth in conservatively managed patients with VS, Stangerup et al. 46 followed 552 patients for a mean of 3.6 years. It was demonstrated that very few observed tumors grew, with 17% of intrameatal and 28.9% of extrameatal lesions growing (p < 0.001). Importantly, for those few tumors that demonstrated growth (> 2 mm), the growth rate was highest within the first 1-2 years of observation, with no tumors growing after 4 years. A strict interpretation of the data in this study suggests that rigorous follow-up is not necessary for these tumors that do not grow within 5 years. Other studies have demonstrated disequilibrium at presentation, new-onset disequilibrium, and tinnitus at diagnosis to increase significantly the odds of tumor growth and failure of conservative management. 1, 26 Additionally, increased tumor size at presentation may increase the risk of growth, with each 1-mm increment increasing the odds of growth by 20%.
Numerous studies have evaluated the quality of life and clinical outcome of conservatively treated patients. One prospective study followed 70 patients for a mean of 43 months and demonstrated that 57% of patients with useful hearing at diagnosis maintained hearing preservation. 15 Additionally, 36-Item Short Form Health Survey scores did not significantly change between diagnosis and last follow-up. However, 36% of tumors exhibited growth, with 59% of patients being conservatively treated at last follow-up. Another prospective study reported that 42.4% of 186 patients had serviceable hearing (vs 58.9% at baseline; p < 0.001) at a median follow-up of 3.6 years.
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Although there was no general reduction in quality of life, there was a significant decrease in the social function subscales. At last follow-up, there was no significant difference in unsteadiness or tinnitus, although a significant decrease in the incidence of vertigo was observed. Only 40% of patients required treatment at last followup. A meta-analysis also reported that 51% of conservatively treated patients (n = 347) had hearing loss at a mean follow-up of 3.2 years, with conservative management failing in only 20% of 1001 patients. 45 Hearing loss is also heavily dependent on hearing function at the time of diagnosis. Another study by Stangerup et al. 47 evaluated 932 patients who received conservative management and demonstrated that 69% of patients with 100% speech discrimination at diagnosis maintained good hearing at ≥ 10 years of follow-up, compared with only 38% of those with discrimination loss at diagnosis. Therefore, there are clearly robust data from large studies to support observation in appropriately selected patients in whom tumors are unlikely to grow and hearing function is likely to be maintained.
Although this management strategy may be suitable for some patients, there is a relatively high rate of clinical failure, with 20%-40% of patients requiring further treatment. 4, 5, 15, 45, 56 A recent study also demonstrated a 13.3% and 41.3% risk of requiring treatment at 2 and 5 years, respectively, following conservative management. 5 Interestingly, patients in whom conservative management is used may have lower quality of life scores at 5-and 10-year follow-up compared with those who received microsurgical treatment or radiosurgery, due to higher rates of hearing loss, tinnitus, and vertigo. 56 However, although a meta-analysis demonstrated that 51% of patients who received conservative management had hearing loss, studies have shown that the majority had normal facial nerve function. 21, 45 Age and tumor size are known to affect the management strategy for VSs, but our data also show that race has a significant impact on the modality of treatment chosen. A multitude of studies throughout all fields of medicine have revealed racial and socioeconomic disparities in the access to health care. Recent studies have also shown numerous disparities in neurosurgery, with African American and Hispanic patients having less access to high-level neurooncological care, and African American patients being significantly more likely to die or to have an adverse discharge disposition following craniotomy for tumor resection. 10, 30 African American patients have also been shown to be significantly less likely to submit claims for radiotherapy following the diagnosis of an astrocytoma, suggesting disparities in receiving the standard of care. 43 In this study, we demonstrate that African American patients were significantly less likely to receive surgical treatment compared with Caucasians (OR 0.50, 95% CI 0.35-0.70; p < 0.0001) despite having slightly larger tumors at diagnosis (1.8 vs 1.6 cm, p = 0.23). As a result, African American patients were nearly twice as likely to receive conservative management compared with Caucasian patients (OR 1.98, 95% CI 1.37-2.85; p = 0.0003). Although a study by McClelland et al. 29 demonstrated that African American race was an independent predictor of increased postoperative mortality rates following VS resection, to our knowledge this is the first study demonstrating a racial disparity in the treatment of VSs. Further studies need to be performed to identify barriers to the access to health care for patients with VSs and other brain tumors so that interventions can be implemented to reduce these disparities.
The SEER database allows for the study of a nationally selected cohort of patients, providing large patient numbers and allowing for the examination of nationwide treatment trends. However, the SEER database has several limitations. Because the SEER data are compiled from 18 regional cancer registries, the database does not uniformly sample the population and thus may bias the results toward centers contributing the largest volume of cases and overrepresented patient groups. For example, whereas SEER includes 25.1% of Caucasians and 26.3% of African Americans in the US, it samples 53.7% and 70.6% of Asians and Native Hawaiian/Pacific Islanders, respectively. Also, various clinical and tumor variables could not be gathered from the database, including patient functional status, duration and nature of symptoms, imaging characteristics, tumor growth rate, and patient comorbidities. Because these factors in addition to patient choice impact the management of VSs, we could not control for these variables. The finding of a racial disparity thus needs to be further investigated. Additionally, the SEER database only contains information on the first course of treatment, preventing the analysis of tumor recurrence and subsequent treatment. The response to treatment is also unknown, preventing the examination of why a small percentage of patients (2%) received both surgery and radiation. This may affect the final treatment distribution in our population. As with all studies involving observation, we cannot exclude the rare possibility of facial nerve schwannomas in our population. Also, treatment characteristics such as radiation modality and dosage are unavailable and thus cannot be examined. However, because we examined a modern cohort of patients, radiotherapy is most likely to be consistent with standard radiosurgery protocols. Finally, as with all national databases, miscoding may be present. However, the National Cancer Institute has a quality improvement program that regularly evaluates the accuracy of SEER data. Also, others have shown the SEER data to accurately record surgical procedures and radiation.
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Conclusions
The incidence of VSs in the US based on a modern cohort of 6225 patients is 1.2 per 100,000 population per year. The majority of patients are Caucasian (83.2%), with cases most commonly being diagnosed in the 6th decade of life. Increasing age was associated with smaller tumors, while non-Caucasian patients presented with larger tumors. Larger tumor size independently increased the likelihood of surgery, and older patients were more likely to undergo radiotherapy. Although many studies have demonstrated improved outcomes with the use of radiotherapy for small-to medium-sized VSs, surgery is still the most commonly used treatment modality for these tumors. Racial disparities also exist in the treatment of VSs, with African American patients being half as likely to receive surgery and nearly twice as likely to receive conservative management despite presenting with larger tumors. Further studies are needed to elucidate the reasons for treatment disparities and to investigate the nationwide trend of resection for the treatment of small VSs.
